Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 20, Issue 6, 2005, Pages 367-374

  Johansson, Annica ^a,g   Zetterberg, Henrik ^a,e   Hampel, Harald ^f   Buerger, Katharina ^f   Prince, Jonathan A ^b   Minthon, Lennart ^c   Wahlund, Lars Olof ^d   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MUNICH   (Germany)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amyloid; Alzheimer's disease; CDC2; Cell cycle; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CELL CYCLE PROTEIN; CELL DIVISION CYCLE PROTEIN 2; PHOSPHATE; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BIOACCUMULATION; CDC2 GENE; CELL CYCLE; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; FREQUENCY ANALYSIS; FRONTAL CORTEX; GENE; GENE LOCATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HIPPOCAMPUS; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENILE PLAQUE; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CDC2 PROTEIN KINASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; TAU PROTEINS;

EID: 27844601188     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088634     Document Type: Article

References (44)

1. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM: Susceptibility locus for Alzheimer's disease on chromosome 10. Science 2000;290:2304-2305.
2. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE: Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000;290:2302-2303.
3. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG: Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 2000;290:2303-2304.
4. Simpson NE, Cann H: Report of the committee on the genetic constitution of chromosome 10. Cytogenet Cell Genet 1990;55:142-152.
5. Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N, Sjogren M, Zetterberg H, Forsell L, Lilius L, Wahlund LO, Rymo L, Prince JA, Blennow K: Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia. Neurosci Lett 2003;340:69-73.
6. Georgi AB, Stukenberg PT, Kirschner MW: Timing of events in mitosis. Curr Biol 2002;12:105-114.
7. Bybee A, Thomas NS: Cell cycle regulation. Blood Rev 1991;5:177-192.
8. Nagy Z, Esiri MM, Cato AM, Smith AD: Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol (Berl) 1997;94:6-15.
9. Grana X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-219.
10. 2-mitosis transition. Biochem Cell Biol 1992;70:954-971.
11. Hyman AA, Karsenti E: Morphogenetic properties of microtubules and mitotic spindle assembly. Cell 1996;84:401-410.
12. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P: Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. Embo J 1994;13:1114-1122.
13. Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annu Rev Neurosci 2001;24:1121-1159.
14. Lindwall G, Cole RD: Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 1984;259:5301-5305.
15. Vincent I, Jicha G, Rosado M, Dickson DW: Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci 1997;17:3588-3598.
16. Pei JJ, Braak H, Gong CX, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF: Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer's disease neurofibrillary degeneration. Acta Neuropathol (Berl) 2002;104:369-376.
17. Meyer JM, Breitner JC: Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am J Med Genet 1998;81:92-97.
18. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
19. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 2. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
23. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B: Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (Berl) 1987;74:209-225.
24. (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-680.
25. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-245.
26. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
27. (1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-258.
28. Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1991.
29. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379.
30. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-388.
31. Husseman JW, Nochlin D, Vincent I: Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol Aging 2000;21:815-828.
32. Dranovsky A, Vincent I, Gregori L, Schwarzman A, Colflesh D, Enghild J, Strittmatter W, Davies P, Goldgaber D: Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiol Aging 2001;22:517-528.
33. Kobayashi S, Ishiguro K, Omori A, Takamatsu M, Arioka M, Imahori K, Uchida T: A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett 1993;335:171-175.
34. Ledesma MD, Correas I, Avila J, Diaz-Nido J: Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease. FEBS Lett 1992;308:218-224.
35. Braak E, Braak H, Mandelkow EM: A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol (Berl) 1994;87:554-567.
36. 1/S cell cycle checkpoint. Cell Tissue Res 2001;305:217-228.
37. Evan G, Littlewood T: A matter of life and cell death. Science 1998;281:1317-1322.
38. Zhang J, Johnson GV: Tau protein is hyperphosphorylated in a site-specific manner in apoptotic neuronal PC12 cells. J Neurochem 2000;75:2346-2357.
39. Vulliet R, Halloran SM, Braun RK, Smith AJ, Lee G: Proline-directed phosphorylation of human Tau protein. J Biol Chem 1992;267:22570-22574.
40. Donovan N, Backer EB, Konishi Y, Bonni A: JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 2002;277:40944-40949.
41. Konishi Y, Lehtinen M, Donovan N, Bonni A: Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 2002;9:1005-1016.
42. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, Smith MA, Perry G, Whitehouse PJ, Taniguchi T: Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 1998;780:260-269.
43. Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS: Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in β-amyloid-induced neuronal death. J Biol Chem 1999;274:19011-19016.
44. Jordan-Sciutto K, Rhodes J, Bowser R: Altered subcellular distribution of transcriptional regulators in response to Abeta peptide and during Alzheimer's disease. Mech Ageing Dev 2001;123:11-20.